ClinicalTrials.gg
RecruitingNCT06030856PALESAUpdated Sep 11, 2023

PrEP Restart for Adolescent Girls and Young Women Using STI Self Testing and Assessment of Risk

An interventional study of STI test kits (NG, CT and TV) for home use and Self Administered Behavioural Risk Assessment in HIV Prevention, sponsored by Wits RHI Research Centre Clinical Research Site. Recruiting at 1 site in South Africa. Open to female participants aged 16 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Wits RHI Research Centre Clinical Research Site · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
16 Years to 20 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Sexually Transmitted Diseases with a site in South Africa — 2 open to participants now, 3 under way, 1 of them phase 3. Sexually Transmitted Diseases · South Africa.

Planned enrollment
27th of 27
50 · median 564
Started
2023
with 3 others
No phase
15 of 30
2 open now
Registered
26th of 30
by date

Among the 30 studies in Sexually Transmitted Diseases with a site in South Africa, this one is the 27th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 15 with no phase, and was the 26th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

2 of the 30 studies in Sexually Transmitted Diseases with a site in South Africa are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 16 Years to 20 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Sexually Transmitted Diseases with a site in South Africa, or all of them as a file.
02

Study summary

This is a pilot randomized trial among 50 AGYW (aged ≥16≤18 years), who discontinued PrEP use within the past 6 months, assigned in a 1:1 ratio to receive: 1) STI self-test kits (Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV)) with in-person instruction at enrolment and telephone/video-based instructions for home use coupled with self-administered behavioural risk assessment or 2) self-administered behavioural risk assessment only (standard of care). All participants will receive comprehensive sexual and reproductive health (SRH) services during their study visits including choice of family planning method initiation and support, and behavioural HIV/STI risk reduction counselling.

Read the detailed description

The PALESA study aims to determine the feasibility of conducting a randomized controlled trial (RCT) to determine the impact of decentralized sexually transmitted infection (STI) point of care (POC) self-testing and risk self-assessment interventions to trigger pre-exposure prophylaxis (PrEP) re-start among adolescent girls and young women (AGYW) in South Africa at potential ongoing risk of re- acquiring STIs and HIV.

This overall study comprises two components that include a formative research study enrolling \~60 participants for qualitative in-depth interviews (IDIs) (this has been completed) and a prospective cohort study (Pilot randomized controlled trial - RCT) enrolling 50 AGYW with both clinical, diagnostic laboratory and nested qualitative methodologies.

The RCT seeks to establish the feasibility of conducting a randomized controlled trial among AGYW in South Africa to determine the impact of decentralized or at-home STI testing [(for Neisseria gonorrhea (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV)] on restarting PrEP relative to a self-administered behavioural risk assessment. Additionally qualitative interviews will be conducted to assess adolescent girls experiences of at-home STI testing, behavioural risk assessment, and re-starting PrEP while participating in the pilot trial through exit interviews.

Objective 1: To determine the feasibility and acceptability of conducting a RCT among South African AGYW to determine the impact of STI self-testing coupled with a self-administered behavioural risk assessment on restarting PrEP relative to a self-administered behavioural risk assessment only

Objective 2: To assess AGYW acceptability of and experiences with use at-home STI testing, self-administered behavioural risk assessment, and re-starting PrEP while participating in the pilot RCT

03

Conditions studied

  • HIV Prevention

Keywords

  • Pre-Exposure Prophylaxis
  • HIV
  • Sexually Transmitted Infection (STI)
04

Who can participate

Ages eligible
16 Years to 20 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the full cohort, all participants must:

    • Be cis-gender adolescent females (16-20 years of age)
    • Be literate
    • Currently sexually active
    • Be willing to participate in in-person and virtual study visits
    • Not be pregnant or planning to be pregnant for the next 6 months
    • Be -negative but not ready to initiate PrEP at the screening and enrolment visit
    • Have used PrEP with subsequent discontinuation within the last 6 months
    • Have no to oral PrEP per self-report
    • Have no indication of possible acute HIV infection, according to South African PrEP guidelines
    • Have their own personal smart phone
    • Willing to provide written /assent to participate in this study

For the subset invited to qualitative interviews, all participants must be:

  • Willing to participate in an IDI at/before their month 6 visit (study exit visit)

Exclusion criteria

Exclusion Criteria:

  • Potential AGYW participants who meet any of the following criteria will be excluded from the study:

    • At Screening and Enrollment, parent/guardian (for those participants \<18 years) is unwilling to provide written
    • At Screening and Enrollment, is already participating in another research study involving drugs, medical devices, or vaccines for STI prevention or treatment.
    • Is not willing to comply with study procedures
    • As determined by the PIs/designee, any current or historical physical health, mental health or social issue or condition that the site investigator or designee determines should exclude participation.
    • Has any other condition that, in the opinion of the PIs/designee, would preclude informed consent, make study participation unsafe, or otherwise interfere with achieving the study objectives.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    STI test kits for home use coupled with self-administered behavioural risk assessment

    The adolescent will receive STI test kits (NG, CT and TV) for home use coupled with self-administered behavioural risk assessment at the screening and enrolment visit.

    Device: STI test kits (NG, CT and TV) for home use · Behavioral: Self Administered Behavioural Risk Assessment

  • Active comparator
    Self-administered behavioural risk assessment only (standard of care)

    The adolescent will receive a self-administered behavioural risk assessment at the screening and enrolment visit

    Behavioral: Self Administered Behavioural Risk Assessment

Interventions

  • DeviceSTI test kits (NG, CT and TV) for home use

    The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.

  • BehavioralSelf Administered Behavioural Risk Assessment

    Self Administered assessment to determine risk of HIV, STIs and pregnancy

06

What researchers measure

Primary outcomes

  1. Number of participants enrolled and retained in the PALESA study

    A recruitment target of 50 adolescent girls and young women and over 90% retention of those participants is achieved

    Time frame: 1 year

  2. Assessing Risk of Acquiring HIV and STIs

    A self administered behavioural risk assessment questionnaire with 16 - 20 questions (which include questions on STI test results), which will tally up a score, will be used to measure how much counselling and guidance will the participants need to restart PrEP. A score of 0 - 7 means medium recommendation to restart PrEP. A score 8-15 means a strong recommendation to restart PrEP. Test results of STIs from the self-testing STI kit are shared on the self-administered behavioural risk assessment questionnaire.

    Time frame: 1 year

  3. Number of participants that restarted PrEP

    There will be a dispensation form for every participant, this form will indicate if PrEP was restarted by the participant, and it will calculate include pill counts when PrEP bottles are returned to the research site

    Time frame: 1 year

  4. PrEP continuation 1 month after re-start

    Dried Blood Spot (DBS) collected to measure tenofovir diphosphate (TFV-DP) level as an objective assessment of adherence to PrEP.

    Time frame: 1 year

  5. Experiences of at-home STI testing, self-administered behavioural risk assessment, and re-starting PrEP

    In-Depth Interviews will be conducted to collect participant's experience while in the study and tools used during the study.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Wits RHI Research Centre
    Hillbrow, Gauteng 2038, South Africa
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data for all outcome measures will be made available after study completion.

Supporting information: Study protocol, Informed consent form

Access criteria: A data request from the PI needs to be made before the data can be released

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2024, 13 months after the start.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 13 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Sep 11, 2023
StartActual
Jul 5, 2023
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2024
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06030856
Lead sponsor
Wits RHI Research Centre Clinical Research Site
Responsible party
Thesla Palanee-Phillips (Director:Clinical Trials, Wits RHI Research Centre Clinical Research Site) — Principal investigator
First posted
Sep 11, 2023
Start date
Jul 5, 2023
Primary completion
Aug 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Sep 11, 2023

Study contacts

Thesla Palanee-Phillips
Contact
TPalanee@wrhi.ac.za
11 358 5471 ext. +27
Krishnaveni Reddy
Contact
KReddy@wrhi.ac.za
11 358 5470 ext. +27

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion